Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

Abstract

Key Points Exposure to melphalan and bortezomib and quality of response to up-front treatment prolong time to second-line therapy in AL amyloidosis. Patients who need second-line therapy after initial response have a good outcome if they are rescued before cardiac progression.